Further evaluation of SNs identified by CCR only or CIBMTR only
| CCR only . | Number of CCR-only SNs . | % of CCR-only cases with a different SN in CIBMTR in the same patient . | % of CCR-only cases with a different SN in CIBMTR within 90 d of the CCR SN in the same patient . | % of CCR-only SNs that are malignant . |
|---|---|---|---|---|
| SN type . | ||||
| All | 315 | 29 | 14 | 75 |
| Breast | 31 | 10 to <15 | None | 74 |
| Brain/CNS | 17 | 29 | None | 5 to <10 |
| Lung | 22 | 23 | 10 to <15 | 100 |
| GI | 37 | 22 | 5 to <10 | 78 |
| GU | 59 | 15 | 5 to <10 | 78 |
| Oropharyngeal | 42 | 67 | 38 | 95 |
| Thyroid | 13 | 5 to <10 | 5 to <10 | 100 |
| Sarcoma | 23 | 43 | 30 | 100 |
| Melanoma | 71 | 28 | 13 | 55 |
| CCR only . | Number of CCR-only SNs . | % of CCR-only cases with a different SN in CIBMTR in the same patient . | % of CCR-only cases with a different SN in CIBMTR within 90 d of the CCR SN in the same patient . | % of CCR-only SNs that are malignant . |
|---|---|---|---|---|
| SN type . | ||||
| All | 315 | 29 | 14 | 75 |
| Breast | 31 | 10 to <15 | None | 74 |
| Brain/CNS | 17 | 29 | None | 5 to <10 |
| Lung | 22 | 23 | 10 to <15 | 100 |
| GI | 37 | 22 | 5 to <10 | 78 |
| GU | 59 | 15 | 5 to <10 | 78 |
| Oropharyngeal | 42 | 67 | 38 | 95 |
| Thyroid | 13 | 5 to <10 | 5 to <10 | 100 |
| Sarcoma | 23 | 43 | 30 | 100 |
| Melanoma | 71 | 28 | 13 | 55 |
| CIBMTR only . | Number of CIBMTR-only SNs . | % of CIBMTR-only cases with a different SN in CCR in the same patient . | % of cases with a different SN in CCR within 90 d of the CIBMTR SN in the same patient . | % of patients who migrated out of CA before the date of the first SN (of this type) . |
|---|---|---|---|---|
| SN type . | ||||
| All | 129 | 19 | 12 | 16 |
| Breast | 14 | 5 to <10 | 5 to <10 | 20 to <25 |
| Brain/CNS | <5 | None | None | NR |
| Lung | 8 | 25 to <30 | 10 to <15 | None |
| GI | 19 | 15 to <20 | 10 to <15 | 20 to <25 |
| GU | 33 | 15 to <20 | 10 to <15 | 10 to <15 |
| Oropharyngeal | 12 | 67 | 50 | 25 to <30 |
| Thyroid | 8 | None | None | 25 to <30 |
| Sarcoma | 9 | 20 to <25 | 10 to <15 | 10 to <15 |
| Melanoma | 23 | 5 to <10 | None | 5 to <10 |
| CIBMTR only . | Number of CIBMTR-only SNs . | % of CIBMTR-only cases with a different SN in CCR in the same patient . | % of cases with a different SN in CCR within 90 d of the CIBMTR SN in the same patient . | % of patients who migrated out of CA before the date of the first SN (of this type) . |
|---|---|---|---|---|
| SN type . | ||||
| All | 129 | 19 | 12 | 16 |
| Breast | 14 | 5 to <10 | 5 to <10 | 20 to <25 |
| Brain/CNS | <5 | None | None | NR |
| Lung | 8 | 25 to <30 | 10 to <15 | None |
| GI | 19 | 15 to <20 | 10 to <15 | 20 to <25 |
| GU | 33 | 15 to <20 | 10 to <15 | 10 to <15 |
| Oropharyngeal | 12 | 67 | 50 | 25 to <30 |
| Thyroid | 8 | None | None | 25 to <30 |
| Sarcoma | 9 | 20 to <25 | 10 to <15 | 10 to <15 |
| Melanoma | 23 | 5 to <10 | None | 5 to <10 |
Different SNs include all of the SN types listed in the table and the categories of NMSC and other and unknown. Percentages are presented in categories to suppress actual cell sizes <5.
NR, not reported because of small sample size.